NY-ESO-1 peptide derivatives, and uses thereof
AssigneeLudwig Institute for Cancer Research
InventorsDanila Valmori, Jean-Charles Cerottini, Pedro Romero
Life of this patent
Estimating the term…
Abstract
The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.
Claims21
An isolated nucleic acid molecule which consists of a nucleotide sequence which encodes a peptide consisting of the amino acid sequence of SEQ ID NO:
- 6, wherein one amino acid in SEQ ID NO:
- 6 other than the C terminal amino acid has been replaced by alanine.
An expression vector comprising a plurality of nucleotide sequences which encode peptides which bind to HLA molecules, wherein at least one of said nucleotide sequences encodes a peptide consisting of the amino acid sequence of SEQ ID NO:
- 6.
An isolated nucleic acid molecule which consists of a nucleotide sequence which encodes a nonapeptide which binds to an HLA molecule and provokes lysis by cytolytic T cells, wherein the amino acid sequence of said nonapeptide consists of
- SLLMWITQX (SEQ ID NO:
- 10)
- wherein X is Ala, Val, Leu, Ile, Pro, Phe, Met, Trp, Gly, Ser, Asp, Glu, Thr or Tyr.
An isolated nucleic acid molecule which encodes a peptide that binds to an HLA molecule and provokes lysis by cytolytic T cells, wherein said peptide consists of the amino acid sequence of SEQ ID NO:
- 6, wherein one amino acid in SEQ ID NO:
- 6 other than the C terminal amino acid has been replaced by alanine.
Dependencies are inferred from the claim text.